~~<i id='3E2AFECAD7'><strike id='3E2AFECAD7'><tt id='3E2AFECAD7'><pre id='3E2AFECAD7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

fashion

author：comprehensive 2025-09-27 12:22:26 - browse：28242

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Do more moles mean more problems? Not so, says new study

Wikipedia

leisure time

hotspot

focus

hotspot

AfederaljudgemadeakeyrulinginalawsuitchallenginganewdrugpricingprogramAdobeWASHINGTON—Afederalcourtj

WSS

Scientists successfully use ultrasound imaging to map brain activity

Report: NIH

Biogen shutters digital health group, ends Apple study, in cost cutting move

Address the ethical violations that led to 'Three Identical Strangers'

Covid vaccines: Private market messier than government rollout

Startling documents reveal new facets of Sacklers' opioid empire

entertainment

fashion

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Duchenne breakthrough therapy leaves behind pioneering families

After a drawn out lobbying fight, ARPA

Supreme Court strikes down use of affirmative action

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Trump demands the U.S. pay no more for drugs than other countries … again

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

leisure time

Sudafed saga points to U.S. issues with evaluating older drugs

Report: NIH

iTeos Therapeutics debuts first data on TIGIT

Medicaid, Medicare dual

Medicaid, Medicare dual

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

hotspot

hotspot

focus

hotspot